Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers—A Pilot Study DOI Creative Commons
Łukasz Bułdak, Aleksandra Bołdys, Estera Skudrzyk

et al.

Metabolites, Journal Year: 2024, Volume and Issue: 14(10), P. 554 - 554

Published: Oct. 16, 2024

: Obesity is one of the major healthcare challenges. It affects in eight people around world and leads to several comorbidities, including type 2 diabetes, hyperlipidemia, arterial hypertension. GLP-1 analogs have become players therapy obesity, leading significant weight loss patients. However, benefits resulting from their usage seem be greater than simple appetite reduction glucose-lowering potential. Recent data show better cardiovascular outcomes, which are connected with improvements course atherosclerosis. Macrophages crucial cells forming progression atherosclerotic lesions. Previously, it was shown that vitro treatment can affect macrophage phenotype, but there a paucity vivo data.

Language: Английский

Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Syndrome Management: A Narrative Review DOI Creative Commons
Silvano Dragonieri, Andrea Portacci, Vitaliano Nicola Quaranta

et al.

Diseases, Journal Year: 2024, Volume and Issue: 12(9), P. 224 - 224

Published: Sept. 23, 2024

Obstructive Sleep Apnea (OSA) is a prevalent disorder characterized by repetitive upper airway obstructions during sleep, leading to intermittent hypoxia and sleep fragmentation. Current treatments, particularly Continuous Positive Airway Pressure (CPAP), face adherence challenges, necessitating novel therapeutic approaches.

Language: Английский

Citations

9
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence DOI Creative Commons
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes

et al.

Receptors, Journal Year: 2025, Volume and Issue: 4(1), P. 2 - 2

Published: Jan. 26, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including dulaglutide, liraglutide, semaglutide, and exenatide, are effective treatments for type 2 diabetes mellitus (T2DM) obesity. These agents mimic the action of endogenous incretin glucagon-like (GLP-1) by enhancing insulin secretion, inhibiting glucagon release, promoting weight loss through appetite suppression. GLP-1RAs have recently been suggested to neuroprotective effects, suggesting their potential as treatment neurodegenerative disorders, such Alzheimer’s disease (AD). AD T2DM share several common pathophysiological mechanisms, resistance, chronic inflammation, oxidative stress, mitochondrial dysfunction. shared mechanisms suggest that therapeutic targeting metabolic dysfunction may also be beneficial conditions. Preclinical studies on in models, both vitro vivo, demonstrated promising reductions amyloid-beta accumulation, decreased tau hyperphosphorylation, improved synaptic plasticity, enhanced neuronal survival. Despite encouraging results from preclinical challenges need addressed before can widely used treatment. Ongoing clinical trials investigating cognitive benefits patients, aiming establish role a option AD. This review aimed examine current literature GLP-1

Language: Английский

Citations

1
Glucagon-like peptide-1 receptor agonism and end-organ protection DOI Creative Commons
Samuel J. Daniels, Cecilia Karlsson, Patrick Schrauwen

et al.

Trends in Endocrinology and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Identification of exendin-4 (a glucagon-like peptide 1 receptor agonist, GLP-1RA) in Gila monster venom may be regarded as one the most serendipitous discoveries recent times. GLP-1RAs are now an established therapeutic approach type 2 diabetes (T2D), body weight management, and cardiovascular (CV) risk protection. Furthermore, there is a growing platform evidence that GLP-1RA has extended benefit renal, hepatic, respiratory, neurological diseases. One can speculate on biological advantage to monster, but for humankind peptides with significant potential improve disease-related outcomes. We report latest mechanisms GLP-1RA-mediated end-organ protection uniquely highlight its future development across multiple disease areas.

Language: Английский

Citations

0
2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide DOI Creative Commons

Melvin D.S. Wong,

Pei‐Hsuan Lin, Wei‐Chen Lin

et al.

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: March 5, 2025

Conjugating two fatty acids (2FAs) to peptide drugs can improve pharmacokinetics and therapeutic effects. However, optimizing FA spacing, chain combination, attachment site simultaneously enhance albumin binding drug efficacy remains challenging. We introduce a multiarm linker technology enabling precise control of 2FA composition, attachment. By applying this modified glucagon-like peptide-1 (GLP-1) screening various 2FA-GLP-1 conjugates differing in linkage, linker, properties for improved affinity, pharmacokinetics, pharmacodynamics, TE-8105 emerged as promising candidate. outperformed semaglutide, showing long-term glycemic control, weight loss, liver health diabetic mice, dose-dependent loss favorable body composition changes obese mice. A distinct advantage over semaglutide is its low-dose reduction steatosis improvement nonalcoholic steatohepatitis The provides versatile platform developing 2FA-peptide therapeutics.

Language: Английский

Citations

0
Oppositely biased glucagon‐like peptide‐1 receptor agonism does not differentially affect lipid metabolism in APOE*3‐Leiden CETP mice DOI Creative Commons
Melanie Modder, Alejandra Tomás,

Salwa Afkir

et al.

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 2, 2025

[D3,G40,K41.C16 diacid]exendin-4 (acyl-ExD3) and [F1,G40,K41.C16 (acyl-ExF1) are oppositely biased glucagon-like peptide-1 (GLP-1) receptor agonists that preferentially promote β-arrestin recruitment or G protein-induced signalling, respectively. The latter is more favourable in glycaemic control induces a steeper reduction body weight diet-induced obese mice. Here, we compared the effects of protein-biased agonist acyl-ExF1 to those β-arrestin-biased acyl-ExD3 on lipid metabolism hyperlipidaemic APOE*3-Leiden.CETP mice were treated with saline, via intraperitoneal injections for 6 weeks intracerebroventricular infusion 18 days. Body composition monitored at regular intervals, as plasma glucose, triglyceride cholesterol levels. At endpoint, injected very low-density lipoprotein (VLDL)-like particles containing glycerol tri[3H]oleate study triglyceride-derived fatty acid uptake by peripheral tissues including brown white adipose tissue (BAT WAT). Upon treatment, gain was prevented glucose levels reduced acyl-ExF1, but circulating lipids not affected either acyl-ExD3. In contrast, central administration strongly levels, did affect Acyl-ExD3 increased [3H]oleate tissue, reaching statistical significance BAT WAT, respectively, vehicle treatment. GLP-1 do differentially mice, while homeostasis prevention pronounced upon

Language: Английский

Citations

0
Importance of weight reduction in type 2 diabetes for the prevention of CVD outcomes: A systematic review of CVOTs DOI
Nebojša Lalić, Aleksandra Jotić, Ljiljana Lukić

et al.

Diabetes Research and Clinical Practice, Journal Year: 2024, Volume and Issue: 216, P. 111816 - 111816

Published: Aug. 13, 2024

Language: Английский

Citations

1
Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction DOI
Tianyu Wang, Qiang Yang, Xinyi Cheng

et al.

Heart Failure Reviews, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 13, 2024

Language: Английский

Citations

1
Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients DOI Open Access
Shauna Levy, Abdallah S. Attia, Rami M. Elshazli

et al.

Cancers, Journal Year: 2024, Volume and Issue: 17(1), P. 78 - 78

Published: Dec. 30, 2024

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in obesity treatment beyond their original development for type-2 diabetes management. This comprehensive study investigated the relationship between GLP-1RA use and cancer incidence individuals with across a 5-year follow-up period. Methods: We conducted large-scale cohort using TriNetX US Collaborative Network database (2013–2023) examining adult patients obesity. The utilized propensity score matching to pair GLP-1RA-treated controls (1:1) nearest neighbor method. Cancer served as primary outcome measure over follow-up, subgroup analyses considering individual agents, patient sex, BMI categories. Results: Analysis revealed cancer-risk reductions associated multiple types compared matched controls. Notable risk were observed gastrointestinal (HR 0.67, 95% CI 0.59–0.75), skin 0.62, 0.55–0.70), breast 0.72, 0.64–0.82), female genital 0.61, 0.53–0.71), prostate 0.68, 0.58–0.80), lymphoid/hematopoietic cancers 0.69, 0.60–0.80). Semaglutide superior protective effects, particularly 0.45, 0.37–0.53). Conversely, liraglutide showed increased risks thyroid 1.70, 1.03–2.82) respiratory 1.62, 1.13–2.32). Conclusions: research provides compelling evidence GLP-1RA’s potential role reduction, semaglutide showing promising results. differential effects among agents emphasize importance of personalized medicine approaches. These findings suggest implications clinical practice future both management prevention.

Language: Английский

Citations

1
Understanding the cardiovascular benefits of glucagon-like peptide-1 (GLP-1) receptor agonists DOI
Lisa M. Raven

Trends in Cardiovascular Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: March 1, 2024

Language: Английский

Citations

0
Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers—A Pilot Study DOI Creative Commons
Łukasz Bułdak, Aleksandra Bołdys, Estera Skudrzyk

et al.

Metabolites, Journal Year: 2024, Volume and Issue: 14(10), P. 554 - 554

Published: Oct. 16, 2024

: Obesity is one of the major healthcare challenges. It affects in eight people around world and leads to several comorbidities, including type 2 diabetes, hyperlipidemia, arterial hypertension. GLP-1 analogs have become players therapy obesity, leading significant weight loss patients. However, benefits resulting from their usage seem be greater than simple appetite reduction glucose-lowering potential. Recent data show better cardiovascular outcomes, which are connected with improvements course atherosclerosis. Macrophages crucial cells forming progression atherosclerotic lesions. Previously, it was shown that vitro treatment can affect macrophage phenotype, but there a paucity vivo data.

Language: Английский

Citations

0